Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature

References

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48–e548.
   PubMed Web of Science ®Google Scholar
• Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691–696.
   PubMedGoogle Scholar
• Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med. 1985;78(1A):29–32.
   PubMed Web of Science ®Google Scholar
• Katusic S, Beard CM, Kurland LT, et al. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med. 1985;78(1A):50–55.
   Web of Science ®Google Scholar
• Linet MS, McLaughlin JK, Harlow SD, et al. Family history of autoimmune disorders and cancer in multiple myeloma. Int J Epidemiol. 1988;17(3):512–513.
   Web of Science ®Google Scholar
• Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer. 1993;29A(2):259–263.
   Web of Science ®Google Scholar
• Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22(2):411–416.
   Web of Science ®Google Scholar
• Djidjik R, Lounici Y, Chergeulaine K, et al. IgD multiple myeloma: clinical, biological features and prognostic value of the serum free light chain assay. Pathol Biol. 2015;63(4–5):210–214.
   Google Scholar
• Robier C, Piribauer M, Beham-Schmid C, et al. IgD-lambda myeloma with extensive free light-chain excretion: a diagnostic pitfall in the identification of monoclonal gammopathies. Clin Chem Lab Med. 2017;55:e137–9.
   Web of Science ®Google Scholar
• Chen L, Fan F, Deng J, et al. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. Ann Hematol. 2019;98(4):963–970.
   PubMed Web of Science ®Google Scholar
• Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398–2404.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854.
   PubMed Web of Science ®Google Scholar
• Hope C, Ollar SJ, Heninger E, et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014;123(21):3305–3315.
   PubMed Web of Science ®Google Scholar
• Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol. 2018;9:788.
   PubMed Web of Science ®Google Scholar
• Schutz N, Marker-Hermann E. [Rheumatoid arthritis and multiple myeloma as comorbidity. Is tocilizumab a therapy option?]. Z Rheumatol. 2012;71:78–82.
   Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20(33):4519–4527.
   PubMed Web of Science ®Google Scholar
• Hauser B, Riches PL, Wilson JF, et al. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology. 2014;53(10):1759–1766.
   PubMed Web of Science ®Google Scholar
• Filkova M, Carvalho J, Norton S, et al. Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis. J Rheumatol. 2017;44(12):1786–1793.
   Web of Science ®Google Scholar
• Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13(11):1109–1113.
   PubMed Web of Science ®Google Scholar
• Saito H, Kakihata H, Nishida Y, et al. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab. 2017;35(4):456–463.
   Web of Science ®Google Scholar
• Kondo S, Kakihata H, Nishida Y, et al. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis. J Bone Miner Metab. 2019;37(2):292–300.
   Web of Science ®Google Scholar
• Pascali E, Pezzoli A, Chiarandini A. Immunofixation: application to the identification of "difficult" monoclonal components. Clin Chem. 1982;28(6):1404–1405.
   Web of Science ®Google Scholar
• Dougados M. Comorbidities in rheumatoid arthritis. Curr Opin Rheumatol. 2016;28(3):282–288.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168(4):378–381.
   PubMedGoogle Scholar
• Kojima M, Itoh H, Hirabayashi K, et al. Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006;202(9):679–685.
   PubMed Web of Science ®Google Scholar
• Goldenberg GJ, Paraskevas F, Israels LG. The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms. Arthritis Rheum. 1969;12(6):569–579.
   Google Scholar
• Zawadzki ZA, Benedek TG. Rheumatoid arthritis, dysproteinemic arthropathy, and paraproteinemia. Arthritis Rheum. 1969;12(6):555–568.
   Google Scholar
• Hamano T, Ishikawa T, Yabe H, et al. [Rheumatoid arthritis terminating in multiple myeloma – a case report]. Rinsho Ketsueki. 1987;28:408–412.
   Google Scholar
• Itoh T, Ohmae Y. [Rheumatoid arthritis terminating in multiple myeloma]. Rinsho Ketsueki. 1994;35(6):547–551.
   Google Scholar
• Inoue F, Ohno T, Furukawa H. [A case of rheumatoid arthritis associated with multiple myeloma]. Jpn J Clin Immun. 1996;19(1):94–99.
   Google Scholar
• Matsumori A, Nishiya K, Chijiwa T, et al. [Two cases of rheumatoid arthritis associated with IgA -type multiple myeloma]. Ryumachi. 2000;40:26–31.
   Google Scholar
• Agarwal V, Sachdev A, Lehl S, et al. Unusual haematological alterations in rheumatoid arthritis. J Postgrad Med. 2004;50(1):60–61.
   Google Scholar
• Alexopoulou A, Dourakis SP, Apostolopoulou A, et al. Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis. Clin Rheumatol. 2005;24(6):669–670.
   Web of Science ®Google Scholar
• Mielke F, Schweigert M. Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. Nat Rev Rheumatol. 2008;4(4):218–221.
   Google Scholar
• Matsuyama Y, Nagashima T, Honne K, et al. Successful treatment of a patient with rheumatoid arthritis and IgA-kappa multiple myeloma with tocilizumab. Intern Med. 2011;50(6):639–642.
   PubMed Web of Science ®Google Scholar
• Sekiguchi Y, Shimada A, Ichikawa K, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(2):2090–2102.
   Web of Science ®Google Scholar
• Liu J, Li J, Chen M, et al. Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: a case report and review of the literature. Medicine. 2016;95(52):e5760.
   Web of Science ®Google Scholar
• Tabata R, Tabata C, Uesugi H, et al. Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate. Int Immunopharmacol. 2019;68:213–217.
   PubMed Web of Science ®Google Scholar
• Lee S, Negoro E, Oki H, et al. Simultaneous presentation of lymphomatoid granulomatosis and multiple myeloma in an immunodeficient patient with rheumatoid arthritis. Intern Med. 2019;58(19):2845–2849.
   Web of Science ®Google Scholar
• Calip GS, Patel PR, Sweiss K, et al. Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. Int J Cancer. 2020;147(5):1300–1305.
   Google Scholar